Capricor Therapeutics, Inc. (NASDAQ:CAPR – Get Free Report)’s stock price traded down 6% on Thursday. The stock traded as low as $8.91 and last traded at $8.9050. Approximately 1,753,203 shares changed hands during mid-day trading, a decline of 44% from the average daily volume of 3,128,219 shares. The stock had previously closed at $9.47.
Analyst Ratings Changes
Several research firms have issued reports on CAPR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Friday, September 11th. Cantor Fitzgerald raised shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Friday, August 14th. Maxim Group lowered shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Oppenheimer reaffirmed an “outperform” rating on shares of Capricor Therapeutics in a report on Thursday, September 17th. Finally, Alliance Global Partners downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a research note on Tuesday, July 28th. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $30.25.
Get Our Latest Stock Report on CAPR
Capricor Therapeutics Trading Down 4.6%
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.11). On average, sell-side analysts predict that Capricor Therapeutics, Inc. will post -1.71 EPS for the current year.
Institutional Trading of Capricor Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC grew its stake in Capricor Therapeutics by 57.8% in the 2nd quarter. Squarepoint Ops LLC now owns 19,731 shares of the biotechnology company’s stock valued at $475,000 after buying an additional 7,231 shares during the last quarter. Montanova Capital LLC lifted its position in Capricor Therapeutics by 7.2% during the second quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock worth $98,554,000 after acquiring an additional 274,184 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Capricor Therapeutics during the second quarter worth approximately $3,895,000. Glenmede Trust Co. NA boosted its holdings in shares of Capricor Therapeutics by 13.2% during the first quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company’s stock worth $1,104,000 after acquiring an additional 4,240 shares during the period. Finally, Bank of America Corp DE grew its position in shares of Capricor Therapeutics by 672.0% in the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock valued at $12,631,000 after purchasing an additional 361,664 shares during the last quarter. Institutional investors own 21.68% of the company’s stock.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc is a biotechnology company focused on developing cell- and exosome-based therapies for serious diseases. The company’s programs are designed to use regenerative medicine and targeted delivery technologies to address conditions with limited treatment options.
Its leading therapeutic candidate is deramiocel, also known as CAP-1002, an allogeneic cell therapy derived from cardiosphere-derived cells. The program has been studied primarily for Duchenne muscular dystrophy, a genetic disorder that causes progressive muscle weakness and cardiac complications.
Featured Articles
- Five stocks we like better than Capricor Therapeutics
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
- First Watch’s Growth Story Meets a Reality Check
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
